MannKind Corp stock (US5638651064): focus on valuation metrics after recent FDA and partnership news

MannKind Corp shares continue to trade in the lower single digits on Nasdaq after recent FDA and partnership developments, putting the focus on valuation ratios and how the biopharma group is currently priced in the United States market.

MannKind Corp shares remain in focus on the Nasdaq as investors digest recent regulatory and partnership developments around its inhaled therapies portfolio and reassess where the stock trades on key valuation metrics in the United States market.

The stock traded around the mid-USD 3 range on Nasdaq in early June 2026, after closing at USD 3.52 on 06/04/2026 according to Benzinga, which reported that MannKind shares rose 4.76% in that session on the United States exchange Benzinga as of 06/05/2026.

Earlier commentary from Robinhood showed MannKind at USD 3.47 per share as of late May 2026 on Nasdaq, underlining that the company is currently valued in the low single-digit dollar range in its home market in the United States Robinhood as of 05/31/2026.

Alongside these price levels, Robinhood highlighted in May 2026 that the U.S. Food and Drug Administration released MannKind from a long-planned postmarketing lung cancer risk trial for its inhaled insulin Afrezza, a regulatory milestone that removes a significant study obligation from the United States pipeline for the diabetes franchise Robinhood as of 05/31/2026.

Investing.com reported in late May 2026 that MannKind has also turned profitable over the last twelve months, citing revenue of about USD 349 million and a gross margin near 75 percent, supported in part by its collaboration work on inhaled therapies such as an inhaled ralinepag formulation for United Therapeutics Investing.com as of 05/29/2026.

Further coverage from Investing.com on 05/29/2026 noted that MannKind shares jumped 38.3 percent in a single session following the announcement of a new dry powder inhalation formulation partnership with United Therapeutics, showing how deal news can translate into sharp moves for the Nasdaq-listed stock Investing.com as of 05/29/2026.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: MannKind Corp
• Sector/industry: Biopharmaceuticals, inhaled therapeutics
• Headquarters/country: Danbury, United States
• Core markets: United States and selected international diabetes and pulmonary arterial hypertension markets
• Key revenue drivers: Inhaled insulin Afrezza and partnered inhaled therapies, including pulmonary arterial hypertension programs
• Home exchange/listing venue: Nasdaq (MNKD)
• Trading currency: USD

MannKind Corp: core business model

MannKind Corp focuses on developing and commercializing inhaled therapeutic products, with Afrezza and partnered pulmonary arterial hypertension therapies forming the core revenue engines across its U.S.-centered biopharma franchise.

Valuation metrics and multiples for MannKind Corp

For investors tracking MannKind Corp on valuation grounds, the most recent twelve-month financial profile provides context for how the current Nasdaq share price relates to fundamentals such as sales and profitability.

Investing.com reported on 05/29/2026 that MannKind generated approximately USD 349 million in revenue over the last twelve months and achieved a gross margin close to 75 percent, indicating a business that has been able to convert a large share of its top line into gross profit in the recent period Investing.com as of 05/29/2026.

With MannKind shares trading around USD 3.47 to USD 3.52 in late May and early June 2026 on Nasdaq, as indicated by Robinhood and Benzinga, this revenue base can be compared with the companys market capitalization to derive sales-based valuation multiples, even though the exact market cap figure is not disclosed in those sources Robinhood as of 05/31/2026.

Morningstar classifies MannKind in the healthcare sector and describes it as a biopharmaceutical company focused on inhaled therapeutic products, including Afrezza for diabetes and inhaled therapies for pulmonary arterial hypertension, a positioning that tends to lead investors to compare its valuation metrics with other specialty pharma and biotech names in the United States healthcare universe Morningstar as of 05/30/2026.

Morningstar also notes that MannKinds Afrezza product, an ultra-rapid-acting inhaled insulin, continues to be a central approved therapy in its portfolio, which investors may factor into expectations about future revenue, margin sustainability and potential valuation re-rating in the U.S. market as inhaled therapeutics become more established in endocrine and pulmonary care Morningstar as of 05/30/2026.

Given that Investing.com highlighted MannKinds shift to profitability in the last twelve months as of 05/29/2026, equity holders may also look at earnings-based measures such as price-to-earnings ratios when sufficient bottom-line data are available, although such precise multiples were not specified in the cited sources and would need to be calculated from detailed financial statements Investing.com as of 05/29/2026.

Conclusion

MannKind Corp remains an actively traded United States biopharmaceutical stock on Nasdaq, with shares around the mid-USD 3 level in early June 2026 after a series of regulatory and partnership headlines.

Recent data points from Investing.com and Robinhood underscore that the company has moved into profitability with several hundred million dollars in trailing revenue while still carrying a relatively low absolute share price, a combination that keeps valuation ratios under scrutiny.

How the Afrezza franchise, new inhaled therapies and collaborations such as the ralinepag program with United Therapeutics develop will likely play a central role in where MannKinds valuation metrics settle over time in the context of the broader United States healthcare sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.